To the full analysis
Recursion Pharmaceuticals stock: growth
RXRXRecursion Pharmaceuticals reported $74.68M in revenue for fiscal 2025, up 26.9% on the prior year, up 79.9% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
87.6%
per year from 2019 to 2025, per share 59%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2019 | |
|---|---|---|
| Revenue | 85.4% | 87.6% |
| Revenue per share | 52.0% | 59.0% |
| Earnings | no data | no data |
| Earnings per share | no data | no data |
| Free cash flow | no data | no data |
| Free cash flow per share | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2019 | $1.71M | −$62.53M | −$60.95M |
| 2020 | $3.41M | −$87.01M | −$52.13M |
| 2021 | $10M | −$186.48M | −$198.41M |
| 2022 | $39.68M | −$239.48M | −$120.88M |
| 2023 | $43.88M | −$328.07M | −$300.33M |
| 2024 | $58.84M | −$463.66M | −$372.87M |
| 2025 | $74.68M | −$644.76M | −$378.28M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Apr 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.